Strategic CDMO ReiThera operates as a contract development and manufacturing organization with GMP capabilities and viral-vector expertise across AAV, Lentivirus, AdV, MVA, and Herpes vectors, presenting a strong partner for gene therapy and advanced-therapy programs seeking scalable manufacturing and process development.

Scaleable Manufacturing With bioreactors up to 2000L, fixed-bed adherence systems, a filling suite, and QC labs, ReiThera can support mid-scale clinical batches and process optimization, offering potential for tech transfer and in-house quality control to reduce timelines.

Strategic Partnerships Recent collaborations with Trellis Research Group, SillaJen, Sabin Vaccine Institute, and AAVantgarde demonstrate a growing network in gene therapy and vaccine production, signaling opportunities for co-development, joint ventures, and expanded service offerings.

Geographic Focus Headquartered in Rome with in-house R&D and GMP facilities, ReiThera is well-positioned to serve European clinical programs and partnerships, potentially enabling faster regulatory alignment and regional supply for EU-based trials.

Market Readiness Active involvement in industry events (ESGCT), ongoing SJ-600 series development, and a proven track record in scalable viral-vector production indicate readiness to engage customers on early manufacturing strategies, tech transfers, and readiness for GMP-scale expansion.